Search Result
Results for "
docking
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-136177
-
|
Phospholipase
|
Inflammation/Immunology
|
Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A2 (sPLA2) through molecular docking .
|
-
-
- HY-153128
-
|
DOCK
|
Inflammation/Immunology
|
DOCK2-IN-1 (compound 3), a CPYPP (HY-110100) analogue, is an inhibitor of DOCK2 as well (IC50=19.1 μM). DOCK2-IN-1 binds to DOCK2 DHR-2 domain in a reversible manner to inhibits its catalytic activity. DOCK2-IN-1 blocks the activation of both chemokine receptor- and antigen receptor-mediated Rac in lymphocytes. DOCK2-IN-1 significantly suppresses chemotactic response and T cell activation .
|
-
-
- HY-110100
-
CPYPP
2 Publications Verification
|
Others
|
Inflammation/Immunology
|
CPYPP is a DOCK2-Rac1 interaction inhibitor. CPYPP binds to DOCK2 DHR-2 domain and inhibits the guanine nucleotide exchange factor (GEF) activity of DOCK2 DHR-2 for Rac1 in a dose-dependent manner with an IC50 of 22.8 µM. CPYPP also inhibits DOCK180 and DOCK5 and less inhibits DOCK9 .
|
-
-
- HY-RS03921
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK1 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK1 Human Pre-designed siRNA Set A
DOCK1 Human Pre-designed siRNA Set A
-
- HY-RS03922
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK10 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK10 Human Pre-designed siRNA Set A
DOCK10 Human Pre-designed siRNA Set A
-
- HY-RS03924
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK2 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK2 Human Pre-designed siRNA Set A
DOCK2 Human Pre-designed siRNA Set A
-
- HY-RS03925
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK3 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK3 Human Pre-designed siRNA Set A
DOCK3 Human Pre-designed siRNA Set A
-
- HY-RS03926
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK4 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK4 Human Pre-designed siRNA Set A
DOCK4 Human Pre-designed siRNA Set A
-
- HY-RS03927
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK5 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK5 Human Pre-designed siRNA Set A
DOCK5 Human Pre-designed siRNA Set A
-
- HY-RS03928
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK6 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK6 Human Pre-designed siRNA Set A
DOCK6 Human Pre-designed siRNA Set A
-
- HY-RS03929
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK7 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK7 Human Pre-designed siRNA Set A
DOCK7 Human Pre-designed siRNA Set A
-
- HY-RS03930
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK8 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK8 Human Pre-designed siRNA Set A
DOCK8 Human Pre-designed siRNA Set A
-
- HY-RS03931
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK9 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK9 Human Pre-designed siRNA Set A
DOCK9 Human Pre-designed siRNA Set A
-
- HY-RS03923
-
|
Small Interfering RNA (siRNA)
|
Others
|
DOCK11 Human Pre-designed siRNA Set A contains three designed siRNAs for DOCK11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
DOCK11 Human Pre-designed siRNA Set A
DOCK11 Human Pre-designed siRNA Set A
-
- HY-124711
-
|
Others
|
Cancer
|
TBOPP is a selective inhibitor of DOCK1 with an IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (Kd of 7.1 μM), has anti-tumor activity for broader types of tumors .
|
-
-
- HY-B0859
-
|
|
|
MCPA is a phenoxy herbicide, and widely used to control annual and perennial broad leaved weeds, including poppy, thistles and docks, in crops such as cereals, rice, linseed, flax, grassland and turf .
|
-
-
- HY-B0859S
-
4-Chloro-2-Methylphenoxyacetic acid-13C8
|
Isotope-Labeled Compounds
|
Others
|
MCPA- 13C8 is the 13C-labeled MCPA. MCPA is a phenoxy herbicide, and widely used to control annual and perennial broad leaved weeds, including poppy, thistles and docks, in crops such as cereals, rice, linseed, flax, grassland and turf[1][2].
|
-
-
- HY-B0859S1
-
|
Isotope-Labeled Compounds
|
Others
|
MCPA-d3 is the deuterium labeled MCPA[1]. MCPA is a phenoxy herbicide, and widely used to control annual and perennial broad leaved weeds, including poppy, thistles and docks, in crops such as cereals, rice, linseed, flax, grassland and turf[2][3].
|
-
-
- HY-114645
-
|
PDK-1
|
Cancer
|
PDK1-IN-RS2 is a mimic of peptide docking motif (PIFtide) and is a substrate-selective PDK1 inhibitor with a Kd of 9 μM. PDK1-IN-RS2 suppresses the activation of the downstream kinases S6K1 by PDK1 .
|
-
-
- HY-153916
-
T417
|
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
TCRS-417 (T417) is a small molecule compound capable of docking to the interface between PBX1 and its cognate DNA target sequence, effectively interfering with PBX1-DNA interaction. TCRS-417 can be used in the research of cancer, developmental disorders, inflammatory disorders, autoimmune diseases or neurodegenerative diseases .
|
-
-
- HY-162262
-
-
-
- HY-102078
-
|
Ras
Apoptosis
|
Cancer
|
ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects .
|
-
-
- HY-157167
-
|
mTOR
|
Neurological Disease
Cancer
|
mTORC1-IN-1 (T1) is a rapamycin homologue (rapalog) and selective mTORC1 inhibitor. mTORC1-IN-1 regulates cell growth and metabolism and is implicated in a variety of diseases including cancer. mTORC1-IN-1 targets mTORC1 by binding to the FKBP12-FRB complex (docking score = −11.6 kcal/mol) .
|
-
-
- HY-139604
-
|
Apoptosis
|
Cancer
|
PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability .
|
-
-
- HY-N0451
-
Acacetin
Maximum Cited Publications
7 Publications Verification
5,7-Dihydroxy-4'-methoxyflavone
|
Apoptosis
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .
|
-
-
- HY-P1906
-
|
CDK
|
Neurological Disease
|
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM .
|
-
-
- HY-P1906A
-
|
CDK
|
Neurological Disease
|
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM .
|
-
-
- HY-N2025
-
|
PPAR
Glucosidase
|
Metabolic Disease
|
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .
|
-
-
- HY-124858
-
|
STAT
JAK
Apoptosis
|
Cardiovascular Disease
Cancer
|
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .
|
-
-
- HY-155465
-
|
HPPD
|
Others
|
HPPD-IN-2 (compound 28) is a herbicide based on HPPD inhibitors. HPPD-IN-2 potently targets AtHPPD and exhibits enhanced safety in canola crops .
|
-
-
- HY-163105
-
|
Microtubule/Tubulin
|
Cancer
|
Tubulin/NEDDylation-IN-1 (compound C11) is a dual inhibitor of tubulin (Microtubule/Tubulin)-NEDDylation (IC50 for tubulin=2.40 μM), which has strong anti-proliferative activity. Neddylation is a protein post-translational modification that covalently tags the ubiquitin-like protein NEDD8 to target proteins. Tubulin/NEDDylation-IN-1 forms hydrogen bonds with residues of tubulin and E1 NEDD8 activating enzyme (NAE) through methoxy and dithiocarbamate groups and inhibits NEDDylation and microtubulin in an ATP-dependent manner. tube polymerization .
|
-
-
- HY-N0451R
-
5,7-Dihydroxy-4'-methoxyflavone (Standard)
|
Apoptosis
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Acacetin (Standard) is the analytical standard of Acacetin. This product is intended for research and analytical applications. Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .
|
-
-
- HY-149523
-
|
Apoptosis
NO Synthase
Caspase
|
Inflammation/Immunology
Cancer
|
Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
|
-
-
- HY-157168
-
|
Trk Receptor
|
Neurological Disease
|
TrkA-IN-6 (compound R48) is a hydrazone-like, selective inhibitor of tropomyosin kinase type A receptor kinase (TrkA). TrkA-IN-6 exhibited a higher cytotoxic effect on U87 GBM cells than Temozolomide (HY-17364), with an IC50 of 68.99 μM .
|
-
-
- HY-144701
-
-
-
- HY-156332
-
|
PARP
|
Cancer
|
TNKS-2-IN-2 is a potent and selective inhibitor of TNKS2 with an IC50 of 22 nM .
|
-
-
- HY-161067
-
|
EGFR
Apoptosis
|
Cancer
|
EGFR-IN-96 (compound 7a) is a thieno[2,3-d]pyrimidine EGFR inhibitor that can induce apoptosis. EGFR-IN-96 arrests the growth of HepG2 cells in the S phase and G2/M phase, and inhibits the growth of cancer cells bearing EGFR wild-type and EGFR T790M .
|
-
-
- HY-155240
-
|
Tyrosinase
|
Cancer
|
Tyrosinase-IN-13 (compound 3c), a derivative of Flurbiprofen (HY-10582), is a potent, non-competitive tyrosinase inhibitor (IC50=68 μM; Ki=36.3 μM). Tyrosinase-IN-13 is cytotoxic against hepatocellular carcinoma (HepG2), colorectal cancer (HT-29), and melanoma (B16F10) .
|
-
-
- HY-157170
-
-
-
- HY-161071
-
|
Others
|
Infection
Cancer
|
Antioxidant/anticancer agent 1 (compound 5) is a pyrimidine-derivatized Schiff base based on pyrimidine hydroxy-1-naphthaldehyde and has antibacterial, antioxidant, antifungal, and anticancer properties. Antioxidant/anticancer agent 1 .
|
-
-
- HY-163109
-
|
Carbonic Anhydrase
|
Infection
|
Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase hCA I and hCA II (Ki: 28.5 nM, 2.2 nM) .
|
-
-
- HY-120294
-
|
CGRP Receptor
TRP Channel
|
Neurological Disease
|
Chrysin 6-C-glucoside 8-C-arabinoside can inhibit the CGRP releasing and the activation of TRPV1 channel. Chrysin 6-C-glucoside 8-C-arabinoside can be used for anti-migraine research .
|
-
-
- HY-149435
-
|
HBV
|
Infection
|
HBV-IN-36 (compound 42) is a HBV inhibior (IC50=2 μM), showing anti-HBV activity with EC50 of 0.58 μM .
|
-
-
- HY-149646
-
|
HDAC
|
Cancer
|
HDAC6-IN-24 (compound N1) is a inhibitor of HDAC6 .
|
-
-
- HY-139144
-
-
-
- HY-157015
-
|
Fungal
|
Infection
|
Antifungal agent 81(G22)exhibitsexcellent in vitro antifungal activities against Valsa mali withIC50values of 0.48 mg/L. Antifungal agent 81also exhibits excellent in vivo protective againstV. maliat 40 mg/L .
|
-
-
- HY-157390
-
-
-
- HY-155737
-
|
Estrogen Receptor/ERR
|
Cardiovascular Disease
|
ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC50=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
|
-
-
- HY-155738
-
|
Estrogen Receptor/ERR
|
Cardiovascular Disease
|
ET receptor antagonist 2 (compound 16j) is an orally active ET receptor antagonist (IC50=0.22 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 2 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
|
-
-
- HY-155739
-
|
Estrogen Receptor/ERR
|
Cardiovascular Disease
|
ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist (IC50=0.26 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 3 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
|
-
- HY-161068
-
-
- HY-143435
-
|
Apoptosis
|
Cancer
|
AG6033 is a potential novel CRBN modulator. AG6033 suppresses various tumor cells by modulating the interactions between CRBN and various antitumor target proteins. AG6033 can cause GSPT1 and IKZF1 degradation. AG6033 induces CRBN-dependent cytotoxic effect .
|
-
- HY-155239
-
|
VEGFR
|
Cancer
|
VEGFR-2-IN-35 (compound 7) is a potent VEGFR-2 inhibitor with IC50=37 nM. VEGFR-2-IN-35 inhibits MCF-7 and HCT 116 cancer cells with IC50 values of 10.56 and 7.07 μM, respectively .
|
-
- HY-162038
-
|
MMP
|
Others
|
RXP03 is a MMPs inhibitor with the Ki of 20 nM, 2.5 nM, 10 nM, 5nM and 105 nM for MMP-2, MMP-8, MMP-9, MMP-11, MMP-14, respectively .
|
-
- HY-W760546
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .
|
-
- HY-157090
-
-
- HY-149018
-
|
Phosphodiesterase (PDE)
|
Cancer
|
ATX inhibitor 22 is a novel inhibitor of ATX (autotaxin) with IC50 of 218 nM but lost its inhibitory activity of LPAR1 .
|
-
- HY-150063
-
|
Penicillin-binding protein (PBP)
Bacterial
|
Infection
|
Antibacterial agent 116 is a benzophenone-containing salicylanilide compound. Antibacterial agent 116 has potent antibacterial activity by inhibiting the peptidoglycan formation. Antibacterial agent 116 is used as a photoaffinity probe to label Acinetobacter baumannii penicillin-binding protein (PBP1b), block the propagation pathway to disrupt the growth of peptidoglycan chain .
|
-
- HY-149763
-
|
Amyloid-β
|
Neurological Disease
|
Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
|
-
- HY-149764
-
|
Amyloid-β
|
Neurological Disease
|
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
|
-
- HY-146282
-
|
GABA Receptor
|
Neurological Disease
|
mGAT-IN-1 (compound 28) is a potent and non-selective GAT inhibitor. mGAT-IN-1 has a high inhibitory potency toward mGAT3, with an IC50 of 2.5 μM and pIC50 of 5.61 .
|
-
- HY-155780
-
|
COX
|
Inflammation/Immunology
|
Anti-inflammatory agent 52 (compound 7j) is an orally active selective COX-2 inhibitor. Anti-inflammatory agent 52 has anti-HT29 transfer activity, which leads to periodic arrest in G2/M phase. Anti-inflammatory agent 52 has safety, moderate ability to suppress inflammation. Anti-inflammatory agent 52 has a rare property of suppressing the development of tumor in mouse model, showing anti-cancer activity .
|
-
- HY-155781
-
|
COX
|
Inflammation/Immunology
|
Anti-inflammatory agent 53 (compound 7c) is an orally active selective COX-2 inhibitor. Anti-inflammatory agent 52 has anti-HT29 transfer activity, which leads to periodic arrest in S phase and G2/M phase. Anti-inflammatory agent 52 has safety, moderate ability to suppress inflammation. Anti-inflammatory agent 52 has a rare property of suppressing the development of tumor in mouse model, showing anti-cancer activity .
|
-
- HY-161063
-
-
- HY-161064
-
|
Dihydrofolate reductase (DHFR)
|
Cancer
|
DHFR-IN-15 (compound 34) is a dihydrofolate reductase (DHFR) inhibitor with potential anticancer activity. DHFR-IN-15 effectively binds to DHFR in cells, reducing DHFR levels to 10 nM .
|
-
- HY-147697
-
|
Histone Demethylase
TNF Receptor
|
Inflammation/Immunology
Cancer
|
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC50 of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity .
|
-
- HY-146280
-
|
GABA Receptor
|
Neurological Disease
Metabolic Disease
|
mGAT3/4-IN-1 (compound 19b) is a potent mGAT3/mGAT4 inhibitor, with pIC50 values of 5.31 and 5.24, respectively. mGAT3/4-IN-1 exhibits a significant tactile allodynia reduction in diabetic neuropathic mice .
|
-
- HY-146281
-
-
- HY-149003
-
|
PARP
Apoptosis
|
Cancer
|
PARP1-IN-10 (compound 12c) is a no-cytotoxicity and potent PARP1 inhibitor with an IC50 value of 50.62 nM in vitro. PARP1-IN-10 causes cell cycle arrest at G2/M phase and apoptosis, and enhances the cytotoxicity of temozolomide (TMZ) .
|
-
- HY-103248
-
Vengicide
|
IRE1
Fungal
Antibiotic
Apoptosis
CDK
|
Infection
Cancer
|
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1906
-
|
CDK
|
Neurological Disease
|
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM .
|
-
- HY-P1906A
-
|
CDK
|
Neurological Disease
|
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM .
|
-
- HY-P10053
-
|
Peptides
|
Metabolic Disease
|
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0859S1
-
|
MCPA-d3 is the deuterium labeled MCPA[1]. MCPA is a phenoxy herbicide, and widely used to control annual and perennial broad leaved weeds, including poppy, thistles and docks, in crops such as cereals, rice, linseed, flax, grassland and turf[2][3].
|
-
-
- HY-B0859S
-
|
MCPA- 13C8 is the 13C-labeled MCPA. MCPA is a phenoxy herbicide, and widely used to control annual and perennial broad leaved weeds, including poppy, thistles and docks, in crops such as cereals, rice, linseed, flax, grassland and turf[1][2].
|
-
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P83123
-
DOK1; docking protein 1; Downstream of tyrosine kinase 1; p62(dok); pp62
|
WB, ICC/IF
|
Human, Mouse, Rat |
-
- HY-P82495
-
BAG3; BIS; BAG family molecular chaperone regulator 3; BAG-3; Bcl-2-associated athanogene 3; Bcl-2-binding protein Bis; docking protein CAIR-1
|
WB
|
Human, Rat |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: